MedTrace Logo

Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis

NCT02912637 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-05-29

No results posted yet for this study

Summary

Chronic lung diseases show a gradual onset of irreversible lung damage which can lead to severe breathing problems and/or respiratory failure. Imaging is central to guiding treatment; however, current techniques are either inaccurate or involve exposure to radiation. Recent developments in lung magnetic resonance imaging (MRI) provide promise as a radiation-free alternative. However, conventional MRI cannot directly show changes in distribution of inhaled air or absorption of gas which are important signs of early lung disease. Recently MRI imaging of the inhaled gas contrast agent Xenon has been developed which can provide this important information. This study aims to determine how Xenon MRI can help determine air flow distribution and gas uptake in the lungs. The investigators will also be able to compare the information from patients with that from healthy volunteers. This should give insight into the processes involved in chronic lung diseases and help evaluate disease extent in patients.

Conditions

Interventions

OTHER

Hyperpolarized Xenon MRI

MRI \& MRS of lung using inhaled hyperpolarized Xenon as a contrast agent

Sponsors & Collaborators

  • University of Sheffield

    collaborator OTHER

  • Papworth Hospital NHS Foundation Trust

    lead OTHER_GOV

Principal Investigators

  • Nicholas J Screaton · Papworth NHS Foundation Trust

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02912637 on ClinicalTrials.gov